Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04101669 · ClinicalTrials.gov registry record · NA

RESET System Pivotal Trial (Rev F)

A NA study of Obesity and Diabetes type2, sponsored by Morphic Medical.

Recruiting
Registry status
NA
Development phase
264
Enrollment target
7
Study locations

NCT04101669 is a NA study of Obesity and Diabetes type2 that is actively recruiting participants, run by Morphic Medical. The registered enrollment target is 264 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04101669, a NA study of Obesity and Diabetes type2, is actively recruiting participants, sponsored by Morphic Medical.

RECRUITING
Registry status
NA
Development phase
264 participants
Enrollment target
7
Study locations

Study Summary

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Conditions Studied

Interventions

  • DEVICE RESET Liner
  • OTHER Sham

Study Locations (7)

District of Columbia

  • MedStar Health Research Institute - Washington D.C.

Florida

  • University of Miami Hospital - Miami

Massachusetts

  • Brigham and Women's Hospital - Boston

Michigan

  • Michigan Medicine, Division of Gastroenterology and Hepatology - Ann Arbor

New York

  • Weill Cornell Medicine - New York

Ohio

  • Cleveland Clinic - Cleveland

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 264 participants
Start Date 2019-09-09
Est. Completion 2026-12-01
Phase NA

Sponsor

Morphic Medical

3 total trials

What the Registry Record Tells You About NCT04101669

The ClinicalTrials.gov registry entry for NCT04101669 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The listed sponsor is Morphic Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which RESET Liner is the first listed.

NCT04101669 reports 7 study locations spanning 7 distinct geographic areas - top geographies include District of Columbia, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04101669 about?

NCT04101669 is a clinical study titled "RESET System Pivotal Trial (Rev F)". A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and eff...

What is the current status of trial NCT04101669?

This trial is currently recruiting. It is a NA study. The enrollment target is 264 participants. The study started on 2019-09-09. Estimated completion is 2026-12-01.

What conditions does trial NCT04101669 study?

This clinical trial studies the following conditions: Obesity, Diabetes type2.

What interventions are being tested in trial NCT04101669?

The interventions under investigation include: RESET Liner (DEVICE), Sham (OTHER).

Who is sponsoring clinical trial NCT04101669?

This trial is sponsored by Morphic Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04101669 being conducted?

This trial has 7 study locations across District of Columbia, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.